SEC Form 25-NSE/A filed by Ambrx Biopharma Inc. (Amendment)

3/7/24 9:46:09 AM ET

$AMAM

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

Get the next $AMAM alert in real time by email

NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION UNDER SECTION 12(b) OF THE SECURITIES EXCHANGE ACT OF 1934.

UNITED STATES

OMB APPROVAL

OMB Number:		3235-0080
Expires:	March 31, 2018
Estimated average burden
hours per response:		1.7

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 25

NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION
UNDER SECTION 12(b) OF THE SECURITIES EXCHANGE ACT OF 1934.

Commission File Number

000-56600

Issuer:	Ambrx Biopharma, Inc.
Exchange:	Nasdaq Stock Market LLC

(Exact name of Issuer as specified in its charter, and name of Exchange where security is listed and/or registered)

Address:	10975 North Torrey Pines Road
	La Jolla	CALIFORNIA	92037
Telephone number:				(858) 875-2400

(Address, including zip code, and telephone number, including area code, of Issuer's principal executive offices)

Common Stock

(Description of class of securities)

Please place an X in the box to designate the rule provision relied upon to strike the class of securities from listing and registration:

17 CFR 240.12d2-2(a)(1)

17 CFR 240.12d2-2(a)(2)

17 CFR 240.12d2-2(a)(3)

17 CFR 240.12d2-2(a)(4)

Pursuant to 17 CFR 240.12d2-2(b), the Exchange has complied with its rules to strike the class of securities from listing and/or withdraw registration on the Exchange. ¹

Pursuant to 17 CFR 240.12d2-2(c), the Issuer has complied with its rules of the Exchange and the requirements of 17 CFR 240.12d-2(c) governing the voluntary withdrawal of the class of securities from listing and registration on the Exchange.

Pursuant to the requirements fo the Securities Exchange Act of 1934, Nasdaq Stock Market LLC certifies that it has reasonable grounds to believe that it meets all of the requirements for filing the Form 25 and has caused this notification to be signed on its behalf by the undersigned duly authorized person.

2024-03-07	By	Tara Petta		Director
Date		Name		Title

¹	Form 25 and attached Notice will be considered compliance with the provisions of 17 CFR 240.19d-1 as applicable. See General Instructions.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Get the next $AMAM alert in real time by email

Date	Price Target	Rating	Analyst
9/25/2023	$15.00	Mkt Outperform	JMP Securities
9/12/2023	$26.00	Buy	BTIG Research
7/31/2023	$29.00	Outperform	RBC Capital Mkts
6/14/2023	$26.00	Buy	B. Riley Securities
6/2/2023	$30.00	Outperform	Oppenheimer
5/19/2023	$25.00	Overweight	Cantor Fitzgerald
4/7/2022	$16.00	Outperform	Robert W. Baird
2/28/2022	$6.00	Neutral	Goldman Sachs

SEC Form 25-NSE/A filed by Ambrx Biopharma Inc. (Amendment)

Chat with this insight

Recent Analyst Ratings for
$AMAM

$AMAM
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

JMP Securities initiated coverage on Ambrx Biopharma with a new price target

BTIG Research initiated coverage on Ambrx Biopharma with a new price target

RBC Capital Mkts initiated coverage on Ambrx Biopharma with a new price target

SEC Form 25-NSE/A filed by Ambrx Biopharma Inc. (Amendment)

Chat with this insight

Recent Analyst Ratings for $AMAM

$AMAM Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

JMP Securities initiated coverage on Ambrx Biopharma with a new price target

BTIG Research initiated coverage on Ambrx Biopharma with a new price target

RBC Capital Mkts initiated coverage on Ambrx Biopharma with a new price target

Recent Analyst Ratings for
$AMAM

$AMAM
Analyst Ratings